http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awaren
-
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awaren
-
Merus annonce la présentation des données cliniques de phase 1 sur le MCLA-158 lors du Symposium sur les cancers gastro-intestinaux 2021 de l'American Society of Clinical Oncology (ASCO)
-
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
-
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
-
Merus N.V. (MRUS) Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
-
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
-
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
-
Merus N.V. (MRUS) Reports Agreement with Sema4 to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
-
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
-
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
-
Merus to Present at the Jefferies Virtual London Healthcare Conference
-
Merus to Present at the Jefferies Virtual London Healthcare Conference
-
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
-
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
-
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
-
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
-
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus N.V. (MRUS) Appoints Andrew Joe, M.D., as Chief Medical Officer
-
Merus N.V. (MRUS) announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
-
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
-
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
-
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
-
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
-
Merus N.V. (MRUS), Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
-
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
-
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
-
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
-
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
-
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
-
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
-
Merus Announces Financial Results for the First Quarter and Provides Business Update
-
Merus Announces Financial Results for the First Quarter and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
-
Merus N.V. (MRUS) Reports Dr. Ton Logtenberg to Resign as CEO, President, Principal Financial Officer & Board Member
-
Merus Announces Chief Executive Officer Transition
-
Merus Announces Chief Executive Officer Transition
-
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update
-
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update
-
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
-
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
-
Merus N.V. (MRUS) and Incyte (INCY) Announce Research Collaboration
-
Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
-
Merus N.V. (Nasdaq: MRUS) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
